$DYAI

DYADIC INTERNATIONAL INC (DYAI): Submission of Matters to a Vote of Security Holders

DYADIC INTERNATIONAL INC (DYAI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001213809 0001213809 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Original reporting
Published Jun 22, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$DYAI
Neutral
medium confidence
Mentioned
$DYAI
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DYAINeutralLow
01

Why it matters

Shareholders approved the board’s discretion to implement a reverse stock split within a ratio range described in the company’s proxy statement; this creates optionality for future capital-market actions but does not confirm execution in this filing.

02

Market read

The most tradable element is the approved reverse-split authorization, which can later translate into execution news; absent that, the filing is mainly governance/optionality information.

03

What to watch

Check whether other proposals (e.g., director election, auditor ratification, say-on-pay) indicate broader governance/financial stress; the split authorization alone may not signal immediate fundamentals.

Relevance 6/10Novelty 4/10Timing: after-hours/filing day following the June 18, 2026 annual meeting results

Background

Dyadic International filed an SEC Form 8-K (Item 5.07) summarizing final voting results from its June 18, 2026 annual meeting.

Company-level read

Ticker impact

$DYAINeutralMedium confidence
Context

Dyadic International reported 2026 annual meeting voting outcomes, including shareholder approval of a potential reverse stock split authorization.

Expected impact

Near-term impact is likely limited unless the company later announces the actual split ratio and effective date; volatility could rise around any subsequent implementation news.

Evidence & confidence

An 8-K item 5.07 provides governance outcomes (authorization approved) rather than an immediate corporate action; the market typically reacts more to the actual split execution than to authorization alone.

Market effects

Limited; reverse-split governance outcomes are company-specific and not a sector-wide catalyst.

Limited; affects only the issuer’s NASDAQ-traded equity.

Minimal; no cross-border deal, regulation, or macro linkage disclosed.

Counterpoint

Because this is only authorization (not execution), traders may overreact; the stock may not move materially until the company announces the actual reverse-split ratio and timing.

Key entities

  • Dyadic International, Inc.

    NASDAQ-listed company that submitted the 8-K with annual meeting voting results.

  • Reverse stock split authorization

    Shareholders approved board authorization to effect a reverse stock split at a ratio within the proxy-stated range.

Related articles

$DYAIMedAI 8/10

Dyadic International Hits Inflection Point as Product Launches Drive Commercial Shift

Dyadic International (NASDAQ:DYAI) said at the Lytham Partners Spring 2026 Investor Conference that it has shifted from an R&D and licensing focus to a commercial-stage protein and enzyme business. It has launched six products in 12 months and secured global distribution and partner deals, including purchase orders for transferrin. The company expects 2026 to be a launch year and reported nearly $3.5 million in upfront milestone fees from Proliant and Inzymes.

$DYAIMedAI 8/10

Dyadic International, Inc.: Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Dyadic International (NASDAQ: DYAI) said it is collaborating with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, associated with Hantavirus Pulmonary Syndrome. The companies plan to assess Dyadic’s C1 microbial platform for rapid, scalable biologic manufacturing, building on prior Andes work and earlier GMP/Phase 1 C1-produced biologics.

$GOOGLMedAI 8/10

Alphabet raises US$25 billion from sought-after bond sale

Alphabet raised $25 billion via an investment-grade bond sale on Aug 6, with about $115 billion in peak demand, according to people familiar with the deal. It sold 10 tranches maturing from 2 to 40 years. The longest-tenor yield premium was 1.3 percentage points over Treasuries. Alphabet plans to issue $ debt twice yearly, after AI-spending concerns had pressured tech bond sentiment.

$GOOGLMedAI 8/10

Alphabet seeks up to $25 billion in latest AI-driven bond sale

Alphabet is seeking to raise $20 billion to $25 billion via a new U.S. bond offering, with notes in up to 10 tranches and maturities from 2 to 40 years, according to regulatory filings and people familiar with the matter. The debt plan follows recent increases in Alphabet’s capex outlook and its first negative free cash flow, with proceeds for general corporate purposes including AI infrastructure and refinancing.

$ETSYMedAI 8/10

Etsy to cut 12% of workforce despite strong quarterly results

Etsy will cut about 220 jobs, or 12% of its workforce, after filing with the SEC, citing a restructuring to speed decisions and support long-term growth. CEO Kruti Patel Goyal said the layoffs are not driven by AI. Despite the cuts, Etsy reported Q2 revenue of $668.3M and raised full-year gross merchandise sales guidance to mid-single digits.

$STIMed

Solidion Technology, Inc.: Solidion Technology Achieves Dramatic Balance Sheet Improvement, Increased Revenues

Solidion Technology (Nasdaq: STI) reported Q2 2026 results, citing a $35 million private placement that it says eliminated going-concern doubt. Cash rose to $27.7 million at June 30, 2026 from $0.2 million at Dec. 31, 2025. Revenue was $124,914 from government grants and product deliveries. Net loss was $2.9 million ($0.35/share).